Litcius/Paper detail

Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results

Kathryn Jean Lucas, Patricia López, Eric Lawitz, Aasim Sheikh, Dov Aizenberg, Stanley H. Hsia, George Goh Bee, John M. Vierling, José Aristeu Fachini Frias, J. White, Yuichiro Eguchi, Donald J. Lazas, Guy Neff, Masato Yoneda, Salvador Augustín, Won Kim, Y. Loeffler, F Schaefer, S. Lamle, Miljen Martić, Clifford A. Brass, Arun J. Sanyal

2020Digestive and Liver Disease51 citationsDOI

Topics & Concepts

MedicinePlaceboSteatohepatitisTolerabilityAgonistInterimInternal medicineAlanine aminotransferaseGastroenterologyPharmacologyEndocrinologyFatty liverAdverse effectReceptorPathologyDiseaseAlternative medicineArchaeologyHistoryLiver Disease Diagnosis and TreatmentPancreatic function and diabetesEndoplasmic Reticulum Stress and Disease
Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results | Litcius